 Imugene Ltd has entered into a research collaboration with Celurlarity Inc to develop a novel oncolytic virus allogeneic CAR T-Cell immunotherapy combination for the treatment of solid tumors. As part of the partnership, Imugene and Celularity will initially collaborate to develop the combination of Imugenes CD19 oncolytic virus technology and Celularitys CD19 targeting allogeneic chimeric antigen receptor CAR T cellular therapy, CyCART-19, for the treatment. 